
ADARx Pharmaceuticals, Inc.
ADRXPricedADARx Pharmaceuticals, Inc. · Nasdaq Global Market · Research source · 424B4 · 2026-09-28 · Latest filing · 10-Q · 2026-11-12 SEC ↗
ADARx priced its IPO at $17, with AbbVie participation and substantial clinical-stage funding needs.
As of the September 28, 2026 Form 424B4, ADARx proposed 26.25 million primary shares at $17.00 and a concurrent AbbVie private placement.
- Business and development direction
ADARx Pharmaceuticals, Inc.
Current business Future development
Key risks
Risk 1
The company has not completed any clinical programs and has no products approved for commercial sale.
Risk 2
The company expects significant losses and may require substantial additional funding, causing future dilution.
Risk 3
Third parties conduct preclinical studies, clinical trials and manufacturing, creating execution and timing dependencies.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | J.P. Morgan Securities LLC | 29.00% | 7,612,500 shares | |
| 2 | Morgan Stanley & Co. LLC | 27.00% | 7,087,500 shares | |
| 3 | TD Securities (USA) LLC | 20.00% | 5,250,000 shares | |
| 4 | UBS Securities LLC | 17.00% | 4,462,500 shares | |
| 5 | LifeSci Capital LLC | 7.00% | 1,837,500 shares |
Ratio = institution commitment ÷ complete source-table total (26,250,000 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.19 | $ / share |
| Total underwriting discount | $31,237,500 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 7; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 7; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗IPO CAPITAL QUALITY
Basis and evidence
424B4 · 2026-09-28
As of the September 28, 2026 Form 424B4, ADARx proposed 26.25 million primary shares at $17.00 and a concurrent AbbVie private placement.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Primary shares · ADARx Pharmaceuticals, Inc. | 26,250,000 | Shares |
| Secondary shares · AbbVie Inc. | 5,233,264 | Shares |
| Shares offered | 26,250,000 | Shares |
| Offering price | $17 | $ / share |
| Gross offering amount | $446,250,000 | $ |
Source and calculation
Shares offered by issuer Reported inputs; each row retains its own source basis.
Shares offered by issuer
Cover and opening disclosure ↗Concurrent private placement shares; contingent on offering closing Reported inputs; each row retains its own source basis.
Concurrent private placement shares; contingent on offering closing
The offering ↗Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 56 row 1; source 117658:117991; SHA256 c35d0d99684db04c463859954d3064380d3fbde785bd3213b6ca8f80d5db98d0 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 5; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 5; source 2129:5814; SHA256 db14ad19263fb38be3f30841a87c33775e2a82969bc780ebaea5052c079f6555 ↗Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 106.8013M | ≈ $1.8156B | |
| Post-offer shares — base/no option | 106,801,325 | — | |
| Post-offer shares — full option | 110,738,825 | — | |
| Capitalization shares — actual | 9,669,578 | — | |
| Capitalization shares — pro forma | 75,318,061 | — | |
| Capitalization shares — pro forma as adjusted | 106,801,325 | — | |
| Shares offered | 26,250,000 | — | |
| Offering price | — | $17 | |
| Gross offering amount | — | $446,250,000 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: actual; Common stock, par value $0.0001 per share; 110,000,000 shares authorized, 9,669,578 shares issued and outstanding, actual 999,999,999 shares authorized, 75,318,061 shares issued and outstanding, pro forma; and 999,999,999 shares authorized, 106,801,325 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma; Common stock, par value $0.0001 per share; 110,000,000 shares authorized, 9,669,578 shares issued and outstanding, actual 999,999,999 shares authorized, 75,318,061 shares issued and outstanding, pro forma; and 999,999,999 shares authorized, 106,801,325 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma as adjusted; Common stock, par value $0.0001 per share; 110,000,000 shares authorized, 9,669,578 shares issued and outstanding, actual 999,999,999 shares authorized, 75,318,061 shares issued and outstanding, pro forma; and 999,999,999 shares authorized, 106,801,325 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $17
Exact input · Post-offer shares — base/no option: 106,801,325
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 110,738,825
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering and concurrent private placement; 106,801,325 shares (or 110,738,825 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 106,801,325
Exact input · Offering price: $17
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $17 × ≈ 106.8013M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
$17 × 106,801,325 = $1,815,622,525 [summary-table-59-base-1-price, summary-table-59-base-1-post]
Exact calculation · Derived whole-issuer equity value: $1,815,622,525
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-09-28
Relationship filters
Select for details · ADARx Pharmaceuticals, Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| our executive officers, directors and stockholders whoOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering and concurrent private placement by any of this group); source scope: of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition |
| our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliatesOwnership as disclosed | — | approximately 54%Beneficial | — | Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering and concurrent private placement by any of this group); source scope: of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placeme; not an additive ownership partition |
| Entities affiliated with OrbiMedBeneficial shares | 23,255,789 | — | — | Number ofshares ofbeneficiallyowned |
| Entities affiliated with LAV FundBeneficial shares | 11,858,655 | — | — | Number ofshares ofbeneficiallyowned |
| Entities affiliated with SR OneBeneficial shares | 8,336,661 | — | — | Number ofshares ofbeneficiallyowned |
| Zhen Li, Ph.D.Beneficial shares | 10,748,214 | — | — | Number ofshares ofbeneficiallyowned |
| BCLS Fund III Investments, LPBeneficial shares | 5,128,970 | — | — | Number ofshares ofbeneficiallyowned |
| A. Robert MacLeod, Ph.D.Beneficial shares | 491,898 | — | — | Number ofshares ofbeneficiallyowned |
| Chen Yu, M.D., M.B.A.Beneficial shares | 3,590,279 | — | — | Number ofshares ofbeneficiallyowned |
| Simeon George, M.D., M.B.A.Beneficial shares | 8,336,661 | — | — | Number ofshares ofbeneficiallyowned |
| Erez Chimovits, M.B.A.Beneficial shares | 9,230,509 | — | — | Number ofshares ofbeneficiallyowned |
| Carl L. Gordon, Ph.D., CFABeneficial shares | 23,255,789 | — | — | Number ofshares ofbeneficiallyowned |
| All current executive officers and directors as a group (14 persons)Beneficial shares | 50,193,162 | — | — | Number ofshares ofbeneficiallyowned |
| Entities affiliated with OrbiMedBeneficial ownership | — | 30.8%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Entities affiliated with OrbiMedBeneficial ownership | — | 21.8%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Entities affiliated with LAV FundBeneficial ownership | — | 15.7%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Entities affiliated with LAV FundBeneficial ownership | — | 11.1%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Entities affiliated with SR OneBeneficial ownership | — | 11.1%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Entities affiliated with SR OneBeneficial ownership | — | 7.8%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Zhen Li, Ph.D.Beneficial ownership | — | 13.4%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Zhen Li, Ph.D.Beneficial ownership | — | 9.6%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| BCLS Fund III Investments, LPBeneficial ownership | — | 6.8%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| BCLS Fund III Investments, LPBeneficial ownership | — | 4.8%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Chen Yu, M.D., M.B.A.Beneficial ownership | — | 4.8%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Chen Yu, M.D., M.B.A.Beneficial ownership | — | 3.4%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Simeon George, M.D., M.B.A.Beneficial ownership | — | 11.1%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Simeon George, M.D., M.B.A.Beneficial ownership | — | 7.8%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Erez Chimovits, M.B.A.Beneficial ownership | — | 12.2%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Erez Chimovits, M.B.A.Beneficial ownership | — | 8.6%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Carl L. Gordon, Ph.D., CFABeneficial ownership | — | 30.8%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| Carl L. Gordon, Ph.D., CFABeneficial ownership | — | 21.8%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| All current executive officers and directors as a group (14 persons)Beneficial ownership | — | 50.2%Beneficial | — | Percentage of sharesbeneficially owned; Beforeoffering |
| All current executive officers and directors as a group (14 persons)Beneficial ownership | — | 36.1%Beneficial | — | Percentage of sharesbeneficially owned; Afteroffering |
| Executive officers, directors, pre-offering >5%stockholders and their respective affiliatesOwnership as disclosed | — | approximately 54%Beneficial | — | Literal complete collective group; Upon closing of offering and concurrent private placement; Approximately54%; August25,2026share basis; no group purchases in offering or concurrent private placement. Percentage applies to the source complete group, not any individual or truncated subgroup; full original conditions retained. |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; non-cumulative voting; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained |
Source and calculation ↗
Source statement; >; source predicate: owned; primary source clause; source condition: assuming no purchase of shares in this offering and concurrent private placement by any of this group); source scope: of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately; not an additive ownership partition
Upon the closing of this offering and concurrent private placement, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately 54% of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placement by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their shares of our common stock. Any of these actions could adversely affect the market price of our common stock.
Source statement; approximately ; source predicate: will, in the aggregate, hold; primary source clause; source condition: assuming no purchase of shares in this offering and concurrent private placement by any of this group); source scope: of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placeme; not an additive ownership partition
Upon the closing of this offering and concurrent private placement, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately 54% of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placement by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their shares of our common stock. Any of these actions could adversely affect the market price of our common stock.
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: Entities affiliated with OrbiMed(1)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: Entities affiliated with LAV Fund(2)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: Entities affiliated with SR One(3)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: Zhen Li, Ph.D.(4)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: BCLS Fund III Investments, LP(5)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: A. Robert MacLeod, Ph.D.(7)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: Chen Yu, M.D., M.B.A.(8)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: Simeon George, M.D., M.B.A.(3)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: Erez Chimovits, M.B.A.(1)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: Carl L. Gordon, Ph.D., CFA(1)
Exact source ownership column: Number ofshares ofbeneficiallyowned; holders may overlap; not an additive partition
Raw source column: Number ofshares ofbeneficiallyowned; source holder: All current executive officers and directors as a group (14 persons)(10)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with OrbiMed(1)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with OrbiMed(1)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with LAV Fund(2)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with LAV Fund(2)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Entities affiliated with SR One(3)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Entities affiliated with SR One(3)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Zhen Li, Ph.D.(4)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Zhen Li, Ph.D.(4)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: BCLS Fund III Investments, LP(5)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: BCLS Fund III Investments, LP(5)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Chen Yu, M.D., M.B.A.(8)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Chen Yu, M.D., M.B.A.(8)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Simeon George, M.D., M.B.A.(3)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Simeon George, M.D., M.B.A.(3)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Erez Chimovits, M.B.A.(1)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Erez Chimovits, M.B.A.(1)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: Carl L. Gordon, Ph.D., CFA(1)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: Carl L. Gordon, Ph.D., CFA(1)
Exact source ownership column: Percentage of sharesbeneficially owned; Beforeoffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Beforeoffering; source holder: All current executive officers and directors as a group (14 persons)(10)
Exact source ownership column: Percentage of sharesbeneficially owned; Afteroffering; holders may overlap; not an additive partition
Raw source column: Percentage of sharesbeneficially owned; Afteroffering; source holder: All current executive officers and directors as a group (14 persons)(10)
Literal complete collective group; Upon closing of offering and concurrent private placement; Approximately54%; August25,2026share basis; no group purchases in offering or concurrent private placement. Percentage applies to the source complete group, not any individual or truncated subgroup; full original conditions retained.
Upon the closing of this offering and concurrent private placement, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and concurrent private placement and their respective affiliates will, in the aggregate, hold approximately 54% of our outstanding common stock (based on the number of shares of our outstanding common stock as of August 25, 2026 and assuming no purchase of shares in this offering and concurrent private placement by any of this group). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily of those of other stockholders, including seeking a premium value for their shares of our common stock. Any of these actions could adversely affect the market price of our common stock.
Literal source per-share voting entitlement; common stock; non-cumulative voting; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained
Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election. Source context: Upon the filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 999,999,999 shares of our common stock, par value $0.0001 per share, and 10,000,000 shares of our preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the closing of this offering, respectively, and of the Delaware General Corporation Law. This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law.
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| WeAfter date of this prospectus · Source conditions apply | 180 days |
| We and our officers, directors, and holders of substantially all of our common stockAfter date of this prospectus · Source conditions apply | 180 days |
| Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)After date of this prospectus · Source conditions apply | 180 days |
Source and calculation
We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.
SEC lock-up paragraph; source 1666316:1667551; SHA256 fee022aa99bd0286e9ac52b1047a46d5eb69d09b2887e725528fce2da1c4a676 ↗We and our officers, directors, and holders of substantially all of our common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This agreement does not apply to any existing employee benefit plans. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements. Shares to be purchased by AbbVie in the concurrent private placement will not be subject to a lock-up agreement but will be restricted shares under Rule 144 with a holding period to begin on the closing date of the concurrent private placement.
SEC lock-up paragraph; source 1619991:1621225; SHA256 562044a6ca982f4a5c431ffd1be16c5f3bc5524182ba56a8b44e3240d75e6a85 ↗Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including, without limitation, shares of our common stock or such other securities
SEC lock-up paragraph; source 1669579:1670795; SHA256 12de0fb4c05b8294fb44424dd0053cfb4535ddca502bc0a98097a9b7f6d7532c ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of this prospectus
- WeWe have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.
- We and our officers, directors, and holders of substantially all of our common stockWe and our officers, directors, and holders of substantially all of our common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This agreement does not apply to any existing employee benefit plans. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements. Shares to be purchased by AbbVie in the concurrent private placement will not be subject to a lock-up agreement but will be restricted shares under Rule 144 with a holding period to begin on the closing date of the concurrent private placement.
- Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties)Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including, without limitation, shares of our common stock or such other securities
| Holder / event | Term / date | Conditions |
|---|---|---|
| We | 180 days | We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering. |
| We and our officers, directors, and holders of substantially all of our common stock | 180 days | We and our officers, directors, and holders of substantially all of our common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This agreement does not apply to any existing employee benefit plans. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements. Shares to be purchased by AbbVie in the concurrent private placement will not be subject to a lock-up agreement but will be restricted shares under Rule 144 with a holding period to begin on the closing date of the concurrent private placement. |
| Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) | 180 days | Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including, without limitation, shares of our common stock or such other securities |
Basis and evidence
We have agreed that we will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of our common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of our common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold in this offering.
SEC lock-up paragraph; source 1666316:1667551; SHA256 fee022aa99bd0286e9ac52b1047a46d5eb69d09b2887e725528fce2da1c4a676 ↗We and our officers, directors, and holders of substantially all of our common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This agreement does not apply to any existing employee benefit plans. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements. Shares to be purchased by AbbVie in the concurrent private placement will not be subject to a lock-up agreement but will be restricted shares under Rule 144 with a holding period to begin on the closing date of the concurrent private placement.
SEC lock-up paragraph; source 1619991:1621225; SHA256 562044a6ca982f4a5c431ffd1be16c5f3bc5524182ba56a8b44e3240d75e6a85 ↗Our directors and executive officers, and substantially all of our shareholders (such persons, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock (including, without limitation, shares of our common stock or such other securities
SEC lock-up paragraph; source 1669579:1670795; SHA256 12de0fb4c05b8294fb44424dd0053cfb4535ddca502bc0a98097a9b7f6d7532c ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
$ · Annual values as reported · ConsolidatedOperating cash flow
$ · Annual values as reported · Consolidated| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss)Consolidated | ($46,360) | ($73,088) |
| Operating cash flowConsolidated | ($48,563) | $262,288 |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2025-12-31 · Consolidated | $66,517 |
| Cash and cash equivalents2024-12-31 · Consolidated | $14,034 |
| Current assets2025-12-31 · Consolidated | $493,375 |
| Current assets2024-12-31 · Consolidated | $225,667 |
| Total assets2025-12-31 · Consolidated | $507,655 |
| Total assets2024-12-31 · Consolidated | $233,454 |
| Current liabilities2025-12-31 · Consolidated | $30,485 |
| Current liabilities2024-12-31 · Consolidated | $8,937 |
| Total liabilities2025-12-31 · Consolidated | $352,288 |
| Total liabilities2024-12-31 · Consolidated | $12,977 |
| Total equity / (deficit)2025-12-31 · Consolidated | ($202,255) |
| Total equity / (deficit)2024-12-31 · Consolidated | ($137,145) |
| General and administrative expensesFY2025 · Consolidated | $20,302 |
| General and administrative expensesFY2024 · Consolidated | $14,876 |
| Cash and cash equivalents2026-06-30 · Consolidated · Unaudited | $58,484 |
| Current assets2026-06-30 · Consolidated · Unaudited | $441,543 |
| Total assets2026-06-30 · Consolidated · Unaudited | $456,332 |
| Current liabilities2026-06-30 · Consolidated · Unaudited | $34,013 |
| Total liabilities2026-06-30 · Consolidated · Unaudited | $349,762 |
| Total equity / (deficit)2026-06-30 · Consolidated · Unaudited | ($251,052) |
| General and administrative expenses6M ended 2026-06-30 · Consolidated | $11,514 |
| General and administrative expenses6M ended 2025-06-30 · Consolidated | $9,253 |
| Net income / (loss)6M ended 2026-06-30 · Consolidated | ($48,426) |
| Net income / (loss)6M ended 2025-06-30 · Consolidated | ($33,644) |
Basis and evidence
Financial quality and runway
Financial quality and runway
Latest supplied financial period is the six months ended June 30, 2026, with audited full-year data for 2024 and 2025. Six-month 2026 revenue was $2.886 million and net loss was $48.426 million; June 30, 2026 cash, cash equivalents and short-term investments were $427.252 million. Debt and going-concern conclusions are not supplied.
EvidenceFinancial review 1Six-month 2026 collaboration revenue was $2.886 million; operating loss was $56.947 million.
+
Six-month 2026 collaboration revenue was $2.886 million; operating loss was $56.947 million.
EvidenceFinancial review 2Net loss increased from $46.360 million in 2024 to $73.088 million in 2025.
+
Net loss increased from $46.360 million in 2024 to $73.088 million in 2025.
EvidenceFinancial review 3The company relies on scaled EGC and smaller-reporting-company disclosure, including only two audited fiscal years.
+
The company relies on scaled EGC and smaller-reporting-company disclosure, including only two audited fiscal years.
MATERIAL CHANGES
The latest material signals and their investor impact are shown below.
Why it mattersThe marketed IPO increased from 21.875 million to 26.25 million shares, increasing primary issuance and proceeds.
Evidence · The offeringWhy it mattersThe preliminary $15.00–$17.00 range became a $17.00 fixed IPO price.
Evidence · Cover and opening disclosureWhy it mattersThe current filing says listing approval was obtained, replacing the prior application and contingency language.
Evidence · Cover and opening disclosure424B40001193125-26-403094 ↗
Loading filing history…
The company has not completed any clinical programs and has no products approved for commercial sale.
- Evidence
- Risk factors ↗
The company expects significant losses and may require substantial additional funding, causing future dilution.
- Evidence
- Risk factors ↗
Third parties conduct preclinical studies, clinical trials and manufacturing, creating execution and timing dependencies.
- Evidence
- Risk factors ↗
Existing officers, directors and principal stockholders may control or significantly influence stockholder matters if acting together.
- Evidence
- Risk factors ↗